Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades NeuBase Therapeutics to Perform

Oppenheimer Downgrades NeuBase Therapeutics to Perform

Oppenheimer analyst Hartaj Singh downgrades NeuBase Therapeutics (NASDAQ:NBSE) from Outperform to Perform.

byBenzinga Newsdesk

October 21, 2022

1 minute read

Oppenheimer analyst Hartaj Singh downgrades NeuBase Therapeutics (NASDAQ:NBSE) from Outperform to Perform.

Raymond James Maintains Outperform on Braze, Raises Price Target to $50

By Benzinga Newsdesk

September 13, 7:01 AM

Raymond James analyst Brian Peterson maintains Braze (NASDAQ:BRZE) with a Outperform and raises the price target from $40 to $50.

BRZE

Wellbeing Digital Introduces Women In Psychedelics, A Network For Female Minds In Psychedelics

By Lara Goldstein

July 18, 2:00 PM

Mental healthcare company Wellbeing Digital Sciences Inc. (OTC: KONEF) and its subsidiary KGK Science Inc. are the founding sponsors of the Women in Psychedelics Network, also known as “WIP.”

CYBN

News

Manchester United Owners To Explore Sale As Glazers Seek New Investment

By Benzinga Newsdesk

November 22, 3:30 PM

- Reuters Citing Sky News

MANU

Gray Television Projects Higher Political Ad Revenues Amid Election Year – Read Why

By Nabaparna Bhattacharya

May 7, 11:04 AM

Gray Television anticipates increased political revenues for Q2 2024, supported by strong core advertising and demand for local content.

GTN

Oppenheimer Downgrades NeuBase Therapeutics to Perform

Related Posts

Raymond James Maintains Outperform on Braze, Raises Price Target to $50

Wellbeing Digital Introduces Women In Psychedelics, A Network For Female Minds In Psychedelics

Manchester United Owners To Explore Sale As Glazers Seek New Investment

Gray Television Projects Higher Political Ad Revenues Amid Election Year – Read Why